Novel Clostridium perfringens enterotoxin suicide gene therapy for selective treatment of claudin-3-and-4-overexpressing tumors

Gene Therapy

Volumn 19, Issue 5, 2012, Pages 494-503

  Walther, W ^a   Petkov, S ^a   Kuvardina, O N ^a   Aumann, J ^a   Kobelt, D ^b   Fichtner, I ^b   Lemm, M ^b   Piontek, J ^c   Blasig, I E ^c   Stein, U ^a   Schlag, P M ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

Author keywords

cancer; claudin; Clostridium perfringens enterotoxin; suicide gene

Indexed keywords

CLAUDIN 3; CLAUDIN 4; CLOSTRIDIUM PERFRINGENS ENTEROTOXIN; ENTEROTOXIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL STRAIN; CELL STRAIN HCT116; CELL STRAIN MCF 7; CLOSTRIDIUM PERFRINGENS; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SUICIDE GENE THERAPY; WILD TYPE;

ANIMALS; BYSTANDER EFFECT; CELL LINE, TUMOR; CLAUDINS; ENTEROTOXINS; GENE THERAPY; GENES, TRANSGENIC, SUICIDE; HCT116 CELLS; HUMANS; MALE; MICE; NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

BACTERIA (MICROORGANISMS); CLOSTRIDIUM; CLOSTRIDIUM PERFRINGENS; MUS;

EID: 84862149017     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.136     Document Type: Article

References (50)

1. Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2007-an update. J Gene Med 2007; 9: 833-842. (Pubitemid 47543250)
2. Walther W, Stein U. Therapeutic genes for cancer gene therapy. Mol Biotechnol 1999; 13: 21-28. (Pubitemid 30066702)
3. Lo HW, Day CP, Hung MC. Cancer-specific gene therapy. Adv Genet 2005; 54: 235-255.
4. Michl P, Gress TM. Bacteria and bacterial toxins as therapeutic agents for solid tumors. Current Cancer Drug Targets 2004; 4: 689-702. (Pubitemid 40013574)
5. Martin V, Cortes ML, deFelipe P, Farsetti A, Calcaterra NB, Izquierdo M. Cancer gene therapy by thyroid hormone-mediated expression of toxin genes. Cancer Res 2000; 60: 3218-3224. (Pubitemid 30407920)
6. Lee EJ, Jameson JL. Cell-specific cre-mediated activation of the diphteria toxin gene in pituitary tumor cells: potential for cytotoxic gene therapy. Hum Gene Ther 2002; 13: 533-542. (Pubitemid 34253154)
7. Li Y, McCadden J, Ferrer F, Kruszewski M, Carducci M, Simons J et al. Prostate-specific expression of the diphteria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer. Cancer Res 2002; 62: 2576-2582. (Pubitemid 34462737)
8. Zheng JY, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vecor specifically expresing diphteria toxin A. Cancer Gene Ther 2003; 10: 764-770. (Pubitemid 37243797)
9. Kreitman RJ. Chimeric fusion proteins-pseudomonas exotoxin based. Curr Opin Investig Drugs 2001; 2: 1282-1293. (Pubitemid 32878610)
10. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammed AK, Puntel M et al. Gene therapymediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci USA 2010; 107: 20021-20026.
11. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 1997; 3: 1362-1368. (Pubitemid 28011036)
12. Husain SR, Puri RK. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside. J Neurooncol 2003; 65: 37-48. (Pubitemid 37441313)
13. Zheng JY, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther 2003; 10: 764-770. (Pubitemid 37243797)
14. Ayesh B, Matouk I, Ohana P, Sughayer MA, Birman T, Ayesh S et al. Inhibition of tumor growth by DT-A expressed under the control of IGF2 P3 and P4 promoter sequences. Mol Ther 2003; 7: 535-541. (Pubitemid 36553423)
15. Bhakdi S, Bayley H, Valeva A, Walev I, Walker B, Kehoe M et al. Staphylococcal a-toxin, streptolysin O, and Escherichia coli hemolysin: prototypes of pore-forming bacterial cytolysins. Arch Microbiol 1996; 165: 73-79. (Pubitemid 26081834)
16. Yang WS, Park SO, Yoon AR, Yoo JY, Kim MK, Yun CO et al. Suicide cancer gene therapy using pore-forming toxin, streptolysin O. Mol Cancer Ther 2006; 5: 1610-1619. (Pubitemid 44070499)
17. Michl P, Buchholz M, Rolke M, Kunsch S, Löhr M, McClane B et al. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001; 121: 678-684. (Pubitemid 32822583)
18. Kominsky SL, Vali M, Korz D, Gabig TG, Weitzman SA, Agani P et al. Clostridium perfringens enterotoxin elicits rapid and specific cytolysis of breast carcinoma cells mediated through tight junction proteins claudin 3 and 4. Am J Pathol 2004; 164: 1627-1633. (Pubitemid 38529765)
19. Johnson EA. Clostridial toxins as therapeutic agents: benefits of nature's most toxic proteins. Annu Rev Microbiol 1999; 53: 551-575. (Pubitemid 29503741)
20. Czeczulin JR, Hanna PC, McClane BA. Cloning, nucleotide sequencing and expression of the Clostridium perfringens enterotoxin gene in Escherichia coli. Infect Immun 1993; 61: 3429-3439. (Pubitemid 23223436)
21. McClane BA. The complex interactions between Clostridium perfringens enterotoxin and epithelial tight junctions. Toxicon 2001; 39: 1781-1791. (Pubitemid 32787009)
22. Smedley III JG, Uzal FA, McClane BA. Indentification of a prepore large-complex in the mechanism of action of Clostridium perfringens enterotoxin. Infect Immun 2007; 75: 2381-2390. (Pubitemid 46744328)
23. Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem 1997; 272: 26652-26658. (Pubitemid 27458889)
24. Kokai-Kun JF, McClane BA. Deletion analysis of the Clostridium perfringens enterotoxin. Clin Infect Dis 1997; 65: 1014-1022. (Pubitemid 27088005)
25. Kokai-Kun JF, Benton K, Wieckowski EU, McClane BA. Identification of a Clostridium perfringens enterotoxin region required for large complex formation and cytotoxicity by random mutagenesis. Infect Immun 1999; 67: 5634-5641. (Pubitemid 29508080)
26. Fujita K, Katahira J, Horiguchi Y, Sonoda N, Furuse M, Tsukita S. Clostridium perfringens enterotoxin binds to the second extracellular loop of claudin-3, a tight junction integral membrane protein. FEBS Lett 2000; 476: 258-2561.
27. Morita K, Furuse M, Fujimoto K, Tsukita S. Claudin multigene family encoding fourtransmembrane domain protein components of tight junction strands. Proc Natl Acad Sci USA 1999; 96: 511-516. (Pubitemid 29061239)
28. Long H, Crean CD, Lee WH, Cummings OW, Gabig TG. Expression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in prostate cancer epithelium. Cancer Res 2001; 61: 7878-7881. (Pubitemid 33049378)
29. Rangel LB, Agarwal R, D¢Souza T, Pizer ES, Alo PL, Lancaster WD et al. Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 2003; 9: 2567-2575. (Pubitemid 36842098)
30. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 2005; 65: 9603-9606. (Pubitemid 41541431)
31. Soini Y. Expression of claudins 1, 2, 3, 4, 5 and 7 in various types of tumors. Histopathol 2005; 46: 551-560. (Pubitemid 40632312)
32. Hewitt KJ, Agarwal R, Morin PJ. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006; 6: 186.
33. Kominsky SL, Tyler B, Sosnowski J, Brady K, Doucet M, Nell D et al. Clostridium perfringens enterotoxin as a novel-targeted therapeutic for brain metastasis. Cancer Res 2007; 67: 7977-7982. (Pubitemid 47395128)
34. Smedley III JG, McLane BA. Fine mapping of the N-terminal cytotoxicity region of Clostridium perfringens enterotoxin by site-directed mutagenesis. Infect Immun 2004; 72: 6914-6923. (Pubitemid 39552358)
35. Santin AD, Cane S, Bellone S, Palmieri M, Siegel ER, Thomas M et al. Treatment of chemotherapy-resistant human ovarian cancer xenografts in C.B-17/SCID mice by intraperitoneal administration of Clostridium perfringens enterotoxin. Cancer Res 2005; 65: 4334-4342. (Pubitemid 40775672)
36. Santin AD, Bellone S, Siegel ER, McKenney JK, Thomas M, Roman JJ et al. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinomas. Clin Cancer Res 2007; 13: 3339-3346. (Pubitemid 46944921)
37. Santin AD, Bellone S, Marizzoni M, Palmieri M, Siegel ER, McKenney JK et al. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma. Cancer 2007; 109: 1312-1322.
38. Jain RK. Delivey of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989; 81: 570-576. (Pubitemid 19104487)
39. Saeki R, Kondoh M, Kakutani H, Tsunoda S-I, Mochizuki Y, Hamakubo T et al. A novel tumor-targeted therapy using a claudin-4-targeting molecule. Mol Pharmacol 2009; 76: 918-926.
40. Saeki R, Kondoh M, Kakutani H, Matsuhisa K, Takahashi A, Suzuki H et al. A claudintargeting molecule as an inhibitor of tumor metastasis. J Pharmacol Exp Ther 2010; 334: 576-582.
41. Kakutani H, Kondoh M, Saeki R, Fuji M, Watanabe Y, Mizoguchi H et al. Claudin-4-targeting of diphteria toxin fragment A using a C-terminal fragment of Clostridium perfringens entrotoxin. Eur J Pharm Biopharm 2010; 75: 213-217.
42. Yao Q, Cao S, Li C, Mengesha A, Low P, Kong B et al. Turn a diarrhoea toxin into a receptor-mediated therapy for plethora of CLDN-4-overexpressing cancers. Biochem Biophys Re Comm 2010; 398: 413-419.
43. Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG et al. Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cell expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther 2009; 8: 1906-1915.
44. Rello S, Stockert JC, Moreno V, Gamez A, Pacheco M, Juarranz A et al. Morphological criteria to distinguish cell death induced by apoptotic and necrotic treatments. Apoptosis 2005; 10: 201-208. (Pubitemid 40558128)
45. McDonel JL. The molecular mode of action of Clostridium perfringens enterotoxin. Am J Clin Nutr 1997; 32: 210-218.
46. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nature Rev Microbiol 2009; 7: 99-109.
47. Chakrabarti G, Zhou X, McLane BA. Death pathways activated in Caco-2 cells by Clostridium perfringens enterotoxin. Infect Immun 2003; 71: 4260-4270. (Pubitemid 36919888)
48. Walther W, Stein U, Schlag PM. Local gene therapy for cancer. In: Stein U, Schlag PM (eds). Regional Therapy For Cancer. Humana Press: Totowa, 2007, pp 181-196.
49. Walther W, Siegel R, Kobelt D, Knösel T, Dietel M, Bembenek A et al. Nonviral intratumoral jet-injection gene transfer in metastatic melanoma and breast cancer: results of phase I clinical trial. Clin Cancer Res 2008; 14: 7545-7553.
50. Winkler L, Gehring C, Wenzel A, Mü ller SL, Piehl C, Krause G et al. Molecular determinants of the interaction between Clostridium perfringens enterotoxin fragments and claudin-3. J Biol Chem 2009; 284: 18863-18872.